CALDARET

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H16N2O3S
Molecular Weight	256.321
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC=C(N2CCNCC2)C(=C1)S(O)(=O)=O

InChI

InChIKey=DCDFLGVJWQIRGH-UHFFFAOYSA-N

InChI=1S/C11H16N2O3S/c1-9-2-3-10(11(8-9)17(14,15)16)13-6-4-12-5-7-13/h2-3,8,12H,4-7H2,1H3,(H,14,15,16)

HIDE SMILES / InChI

Molecular Formula	C11H16N2O3S
Molecular Weight	256.321
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT00078013 | https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19970618&CC=EP&NR=0779283A1&KC=A1 | https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20030213&CC=WO&NR=03011296A1&KC=A1

Caldaret is intracardiac calcium (Ca2+) handling modulator whose cardioprotective actions are presumed to be due to inhibition of the NCX exchanger and increasing the uptake of Ca2+ via the sarcoplasmic reticulum (SR). Unfortunately, Caldaret failed to demonstrate efficacy in Phase II clinical trials as an adjunct to standard therapy with primary percutaneous coronary intervention patients diagnosed as having an acute myocardial infarction

Originator

Approval Year

PubMed

Title	Date	PubMed
Effect of caldaret on the incidence of severe left ventricular dysfunction in patients with ST-elevation myocardial infarction undergoing primary coronary intervention.	2009-01-01	19101220
Caldaret, an intracellular Ca2+ handling modulator, limits infarct size of reperfused canine heart.	2007-02	17299242
Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study.	2006-11	17030521
A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design.	2004-06	15190528
Breast-feeding may reduce later blood pressure.	2004-03-16	15023898

Patents

Sample Use Guides

In Vivo Use Guide

4.5 mg/kg/48 hours

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:33:39 GMT 2025` Edited by `admin` on `Mon Mar 31 18:33:39 GMT 2025`
Record UNII	9L3Y3IJ2HI
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CALDARET

Official Name

English

MCC-135

Preferred Name

English

caldaret [INN]

Common Name

English

MCC135

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C333